Recent research conducted by a team at the University of Queensland has made a groundbreaking discovery in the fight against two lethal viruses, Nipah and Hendra. These viruses are known for their high fatality rates and lack of approved vaccines or cures, making this research of significant importance.
Introduction to the Viruses
Nipah and Hendra viruses belong to the family of henipaviruses and are transmitted from animals to humans, often leading to severe respiratory and neurological issues. The first identification of the Hendra virus occurred in Brisbane in 1994, with Nipah outbreaks reported predominantly in Bangladesh and other Asian countries.
Discovery of the Nanobody DS90
Under the leadership of Professor Daniel Watterson and Dr. Ariel Isaacs, the researchers have isolated a nanobody named DS90. This innovative therapeutic agent is noteworthy for being only one-tenth the size of a traditional antibody, yet it has the capability to access hard-to-reach areas of the viruses, effectively blocking infection. The implications of this discovery are substantial, as stated by Dr. Isaacs:
“Nanobodies are also easier to produce and more stable at higher temperatures than traditional antibodies, so we are very excited about the potential of our discovery to lead to new treatments.”
Research Methodology
The nanobody DS90 was derived from the immune cells of an alpaca named Pedro, thanks to the collaborative efforts with Universidad Austral de Chile. The process of isolating the nanobodies was facilitated by a unique platform developed by Professor Alejandro Rojas-Fernandez.
The research team utilized cryogenic electron microscopy at UQ's Center for Microscopy & Microanalysis to observe how the DS90 nanobody interacted with the viral proteins. This technique provided detailed visuals of how the nanobody binds to the virus:
- Allows binding to deep pockets within the virus structure.
- Offers a potential pathway for more effective viral neutralization unlike traditional antibodies.
Impact on Viral Mutations
One of the remarkable findings of this study is the effectiveness of DS90 in conjunction with a developmental antibody therapy known as m102.4. This combination has shown to prevent the Nipah virus from mutating, which is critical in the long-term management of outbreaks:
| Combination | Effect |
|---|---|
| DS90 + m102.4 | Prevents Nipah virus from mutating |
Future Directions
The research emphasizes the urgent need to translate these findings into clinical applications, particularly for scenarios involving outbreaks of Hendra or Nipah viruses. The team aims to develop a scalable and effective therapeutic strategy based on the nanobody:
- Transition findings into clinical trials.
- Prepare for potential outbreaks by developing rapid response treatments.
- Investigate further applications of nanobodies in combating other viruses.
Conclusion
This study marks a significant step in virology and therapeutics, especially given the increasing threat posed by zoonotic diseases. As Professor Rojas-Fernandez aptly summarizes:
“Together with UQ, we aimed to construct a broad barrier against future pandemic viruses based on scalable antiviral nanobodies—this fantastic work is just the beginning.”
Additional Information
For further reading, the findings are detailed in the publication:
A nanobody-based therapeutic targeting Nipah virus limits viral escape published in Nature Structural & Molecular Biology (2025).
References
Credit: University of Queensland
Discussion